Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma

NCT02528643 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT02528643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02528643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 9, 2015
Completion date
February 9, 2021
Enrollment
165 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma